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Visceral leishmaniasis is deadly if not treated, and development of a vaccine with long-term immunity
remains a challenge. In this study, we showed that cationic distearoyl phosphatidylcholine (DSPC) liposomes,
when used as vaccine adjuvant with the immunodominant 63-kDa glycoprotein (gp63) of Leishmania donovani
promastigotes, induced significant protection against progressive visceral leishmaniasis in susceptible BALB/c
mice. gp63 used without adjuvant elicited partial protection but in association with liposomes exhibited
marked resistance in both the livers and spleens of the mice challenged 10 days after the last vaccination. The
protective efficacy of liposomal gp63 vaccination was dose dependent, with 2.5 g of protein showing optimal
protection. The immunity conferred by this vaccine formulation was durable, as mice challenged 12 weeks after
immunization were still protected, and the infection was controlled for at least 3 months postchallenge.
Production of gamma interferon (IFN-) and interleukin-4 (IL-4) by splenic T cells, and of serum immuno-
globulin G1 (IgG1) and IgG2a following immunization, suggested that a mixed Th1/Th2 response had been
induced following immunization. However, control of disease progression and parasitic burden in mice
vaccinated with gp63 in cationic DSPC liposomes was associated with enhancement of antigen-specific IFN-
and downregulation of IL-4, demonstrating a Th1 bias. Long-term immunity elicited by this vaccine corre-
sponded to, in addition to the presence of antigen-specific Th1, CD8 T-cell responses. Our results demon-
strated that stable cationic liposomes containing gp63 acted as a potent adjuvant for protein antigen to induce
long-term protection against L. donovani that represents an alternative to DNA vaccination.
Leishmaniasis is an infectious disease complex caused by
several species that are members of the protozoan parasite
genus Leishmania. In humans, disease manifestation ranges
from self-healing cutaneous lesions to life-threatening visceral
leishmaniasis (VL). This disease complex affects 12 million
people, and there are 1.5 million new cases annually (42). VL,
caused by Leishmania donovani and Leishmania chagasi, re-
mains the main agent of morbidity and mortality in leishman-
iasis, with hundreds and thousands of people dying in recent
epidemics in Sudan and India.
The parasite has a simple life cycle, and abundant clinical
and experimental evidence indicates that of all the parasitic
diseases, leishmaniasis in particular should be an appropriate
target for effective control through vaccination. There are,
however, no vaccines in routine use against any form of the
disease (29, 42). The fundamental basis of vaccination is the
generation and maintenance of an antigen-specific immune
response sufficient to mediate protection upon infectious chal-
lenge. Currently available vaccines against a variety of infec-
tious diseases mediate protection by a long-lived humoral re-
sponse through the production of antibodies. For diseases such
as tuberculosis, malaria, human immunodeficiency virus infec-
tion, and leishmaniasis, however, the cellular immune response
comprising primarily Th1 and CD8 effector T cells has been
shown to be critical for mediating protection against infection
(60). In experimental models of cutaneous leishmaniasis (CL)
in which CD4-positive (CD4) Th responses are driven toward
a polarized Th1, protection can be achieved by vaccination.
But such vaccines do not generate potent and durable re-
sponses, and protection wanes after a few weeks (14, 18).
Induction of long-term protection against leishmaniasis re-
quires the generation of memory T cells, probably of both
CD4 and CD8 lineages (16, 27, 77). These are maintained
by the continued presence of antigens through the activity of
live persistent parasites or DNA vaccines (2, 15, 69). Thus,
deliberate inoculation of virulent organisms by a process
known as leishmanization is still used in some countries and
remains the gold standard for vaccination and life-long protec-
tion (30). However, logistic problems of safety and manufac-
turing considerations restrict the use of this procedure, and
DNA vaccines are far less potent for inducing immune re-
sponses in humans than in rodents (15). One recent approach
for generating sustained cellular immunity in vivo against leish-
manial proteins is the use of Toll-like receptor agonists as
nonreplicating vaccine adjuvants. CpG oligonucleotides, which
represent one of the potent inducers of innate and adaptive
immunity, are effective when high doses of antigens are ad-
ministered (39, 53). Therefore, there remains a need for new
nonreplicating vaccine adjuvants capable of eliciting strong
cellular immune responses.
Cationic liposomes have been shown to markedly potentiate
activation of immune response to plasmid DNA and oligonu-
cleotides (24, 75). More recently, the induction of cell-medi-
ated immune response to poorly immunogenic protein and
peptide antigens has been made possible through the use of
positively charged liposome carriers (5, 44). Although these
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vesicles alone are relatively nonimmunogenic, their adjuvant
potency toward the associated antigen is due in part to the
efficient delivery of the antigen to professional antigen-pre-
senting cells (APCs), including macrophages and dendritic
cells (11, 45). It is well established that liposomes channel
protein and peptide antigens into the major histocompatibility
complex class II pathways of APCs, resulting in enhanced
antibody and antigen-specific T-cell proliferative response
(50). In addition, there have been reports of the use of cationic
liposomes for the generation of CD8 T-cell response, which
requires antigen presentation in the context of the major his-
tocompatibility complex class I pathway (5, 17, 44). Stable
liposomes formulated with distearoyl phosphatidylcholine
(DSPC), a saturated phospholipid with a high transition tem-
perature and with cholesterol, reduced clearance from blood
and enhanced cationic lipid-mediated endosomal membrane
destabilization (17, 73). Thus, we believe that cationic DSPC
liposomes with cholesterol would not only deliver antigens
more efficiently to the cytosol for eliciting a CD8 T-cell re-
sponse but would also have the added advantage of persistent
antigen presentation through prolonged circulation, enabling
the possibility of durable immunity induced by protein-based
vaccination.
Although genome-sequencing projects now provide a pleth-
ora of potential vaccine candidates for treatment of leishman-
iasis, few criteria exist for selecting among them, and choosing
the antigen remains a largely empirical procedure (42). Exten-
sive studies in the last decade have, nonetheless, led to the
identification of a number of defined protein antigens having
significant vaccine potential. These studies, however, have fo-
cused almost entirely on treatment of CL, and VL has re-
mained a neglected disease. However, the limited experimen-
tal and clinical evidence available indicates that the same
vaccine/antigen might not work for all cases of leishmaniasis
(29, 37). For example, differences have been observed with the
63-kDa (gp63) glycoprotein and with the Leishmania homo-
logue of the receptor for activated C kinase (LACK), antigens
that have received maximum attention in studies of CL treat-
ment (36). Although vaccination with gp63, in its protein and
DNA forms, has been largely unsuccessful or only partially
protective, immunization with LACK induced strong protec-
tive and durable immunity against L. major (36). Interestingly,
L. donovani LACK failed to induce protection against VL (37)
and induced no response in the peripheral blood mononuclear
cells of individuals cured of L. infantum or L. donovani infec-
tion (33). Whereas LACK is an essential molecule for L. major
survival in mammalian hosts (28), gp63 expression corresponds
to avirulence in these parasites (25, 26, 43). Conversely, gp63
corresponds to the infective stage and virulence of diffused
cutaneous and visceralizing species of Leishmania (67, 72).
Moreover, T cells from patients who had recovered from leish-
maniasis responded in vitro to gp63 (57, 58). Further, kala-azar
patients responded largely through a humoral response di-
rected toward gp63 (32, 51, 52). gp63 could thus be the key
antigen for vaccination against VL, but apart from our prelim-
inary report (1), no vaccine study of any form of L. donovani
gp63 has been carried out for this disease.
In this study, we investigated whether gp63 purified from L.
donovani formulated in cationic DSPC liposomes could induce
a protective response to a visceral disease in BALB/c mice. We
report that L. donovani gp63 is highly immunogenic in associ-
ation with these vesicles and can prevent infection in virulent
challenges using L. donovani parasites not only after a short
vaccination protocol but also 12 weeks after immunization.
Interestingly, we find that the protective immune response
induced by gp63 contained within liposomes is dependent on
the dose of the antigen, with the optimum dose eliciting max-
imum immunogenicity and protection. Our report further
demonstrates sustained immunity through the use of gp63-
specific CD4 and CD8 T cells that control chronic infection.
MATERIALS AND METHODS
Reagents and antibodies. M199 medium, RPMI 1640 medium, HEPES, pen-
icillin-streptomycin, sodium bicarbonate, glutamine, fetal bovine serum (FBS),
leupeptin, EDTA, iodoacetamide, phenylmethylsulfonyl fluoride, octyl--D-glu-
copyranoside, -methyl-D-mannoside, Zwittergent, DEAE-cellulose, complete
Freund’s adjuvant, incomplete Freund’s adjuvant, DSPC, bovine serum albumin,
3,3-diaminobenzidine tetrahydrochloride, -mercaptoethanol, sulfanilamide,
N-(1-naphthylethylene diamine hydrochloride), o-phenylene diamine dihydro-
chloride, Tween 20, brefeldin A, sodium azide, saponin, paraformaldehyde, and
poly-L-lysine were purchased from Sigma-Aldrich, St. Louis, MO. Cholesterol
and stearylamine were obtained from the Center for Biotechnology, New Delhi,
India, and Fluka, Switzerland, respectively. Concanavalin A (ConA)-Sepharose
resin was obtained from Amersham Biosciences, Piscataway, NJ. Horseradish
peroxidase-conjugated anti-mouse immunoglobulin G1 (IgG1) and IgG2a, fluo-
rescein isothiocyanate (FITC)-conjugated monoclonal antibodies (MAbs) to
mouse CD4 and CD8, phycoerythrin-labeled anti-mouse gamma interferon
(IFN-) and interleukin-4 (IL-4), and Perm-2 buffer were purchased from BD
Biosciences, San Diego, CA.
Animals and parasites. BALB/c mice, reared in the animal care facility of the
institute under pathogen-free conditions, were used at 4 to 6 weeks for experi-
mental purposes with prior approval from the Animal Ethics Committee of the
Indian Institute of Chemical Biology. An Indian strain of L. donovani (MHOM/
IN/83/AG83) was maintained by passage in Syrian hamsters. Amastigotes were
isolated from infected hamster spleens and allowed to transform to promasti-
gotes by cultivation at 22°C in M199 medium (pH 7.4) supplemented with 20%
heat-inactivated FBS, 2 mM glutamine, 25 mM HEPES, 100 U/ml of penicillin
G-sodium and 100 g/ml of streptomycin sulfate. Parasites were checked and
enumerated by counting in a hemocytometer on day 6 after first the transfor-
mation and every 72 h thereafter. Designated parasites from stationary-phase
cultures were diluted in fresh medium with the same composition as that men-
tioned above to maintain an average density of 2  106 cells/ml (34).
Isolation of gp63. Soluble leishmanial antigens (SLAg) were extracted from
stationary-phase L. donovani promastigotes harvested after the second passage
as detailed earlier (1). Briefly, 1  1010 cells were suspended in cold 5 mM
Tris-HCl buffer (pH 7.6) containing 5 g/ml of leupeptin, 1 mM EDTA, 1 mM
phenylmethylsulfonyl fluoride, and 1 mM iodoacetamide (lysis buffer). The sus-
pension was vortexed six times for 2 min each time with a 10-min interval on ice.
The parasite suspension was then centrifuged at 2,310  g for 10 min, and the
pellet was collected. The crude ghost-membrane pellet was resuspended in 10 ml
of the same buffer and sonicated three times for 1 min each time on ice. The
suspension thus obtained was solubilized with lysis buffer containing 1% (wt/vol)
octyl--D-glucopyranoside overnight at 4°C and was finally ultracentrifuged for
1 h at 100,000  g (1). The supernatant containing SLAg was used for purifica-
tion of gp63 as described previously (55) with slight modifications. Two milli-
grams of SLAg was applied at a flow rate of 3 ml/h to 1 ml ConA-Sepharose resin
preequilibrated in the buffer used for SLAg preparation containing 1% octyl--
D-glucopyranoside and maintained at 4°C. Unbound protein was washed off the
column with the same buffer, and bound material was eluted at 10 ml/h with
linear 0 to 0.5 M -methyl-D-mannoside gradient in wash buffer. The amount of
protein was estimated in the fractions (0.5 ml) collected during elution and
analyzed by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) (1). The gp63-containing peak fractions were pooled, concen-
trated, and dialyzed against 5 mM Tris-HCl (pH 8.5) with 0.2% Zwittergent 3.12.
The sample (800 g of protein) was run on a 5-ml DEAE-cellulose column that
was preequilibrated in the same buffer used for dialysis. Under these conditions
the anion exchanger readily bound gp63. Following thorough washing, the bound
protein was eluted with a gradient of 0 to 500 mM NaCl in the same buffer at a
flow rate of 6 ml/h. Peak fractions obtained with NaCl elution were run on 10%
SDS-PAGE, and the gel was stained with ammoniacal silver nitrate solution (74).
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The purity of the protein was further confirmed by two-dimensional PAGE (46),
which included staining with ammoniacal silver nitrate solution.
Pure gp63 was used to raise antiserum in a rabbit (immunization with 150 g
of gp63 in complete Freund’s adjuvant and boosting twice with 100 g of protein
in incomplete Freund’s adjuvant). Native gp63 was obtained in mass by incubat-
ing SLAg with anti-gp63 rabbit IgG coupled to CNBr-activated Sepharose. The
protein was subjected to NH2-terminal sequencing using a Procise sequence
analyzer (Applied Biosystems).
Entrapment of gp63 in liposomes. Liposomes containing gp63 were prepared
by detergent dialysis method as described earlier (55, 56) with slight modifica-
tion. DSPC, cholesterol, and stearylamine (at a molar ratio of 7:2:2) mixed with
octyl--D-glucopyranoside (15 mg/10 mg lipids) were dissolved in chloroform and
dried to produce a thin film. gp63 (100 to 120 g) isolated from an anti-gp63
immunoaffinity column was added to 10 mg lipid film and sonicated in an
ultrasonicator for 30 s. The lipid-protein mixture was dialyzed overnight to
remove detergent, and excess free antigen was removed by centrifugation at
100,000  g for 1 h at 4°C. The level of incorporation ranged between 80 and
85%.
Injection of mice. BALB/c mice were immunized by three intraperitoneal (i.p.)
injections at 2-week intervals with graded doses (0.6 to 10 g) or 2.5 g of gp63
free in phosphate-buffered saline (PBS) or entrapped in liposomes (200 l).
Animals receiving only PBS or empty liposomes served as controls. At 10 days or
12 weeks postimmunization, groups of mice were either sacrificed for immuno-
logical assays or challenged intravenously with 2.5  107 freshly transformed L.
donovani promastigotes (34).
The protective capacity of spleen cells from mice that had been vaccinated
with PBS or with free gp63 or gp63 in association with liposomes was assessed by
adoptive transfer experiments (69). Single-cell suspensions of 20 million pooled
splenocytes from three mice from each experimental group were injected i.p. into
syngeneic BALB/c mice, and infections were detected 7 days later and monitored
for 3 months.
Delayed-type hypersensitivity (DTH). Levels of DTH were determined as an
index of cell-mediated immunity as described earlier (1). The response was
evaluated at 24 h by measuring the difference in swelling between two hind
footpads, one injected with 50 l of PBS alone and the other with PBS containing
L. donovani membrane antigens (LAg) (800 g/ml).
Measurement of gp63-specific antibody responses. Serum samples from indi-
vidual mice of each group were obtained before and after infection and analyzed
for the presence of gp63-specific antibodies. Ninety-six-well Maxisorp plates
(Nunc, Roskilde, Denmark) were coated with gp63 (5 g/ml) diluted in 0.02 M
phosphate buffer (pH 7.5) overnight at 4°C. Plates were blocked with 1% bovine
serum albumin in PBS at room temperature for 3 h to prevent nonspecific
binding. After being washed with PBS containing 0.05% Tween 20, the plates
were incubated overnight with a 1:100 dilution of mice serum samples at 4°C.
The next day, the plates were incubated for 3 h at room temperature with
horseradish peroxidase-conjugated goat anti-mouse IgG1 or IgG2a diluted
1:1,000 in blocking buffer. Substrate solution (0.8 mg/ml o-phenylene diamine
dihydrochloride–0.05 M phosphate-citrate buffer [pH 5.0] containing 0.04%
H2O2) (100 l) was added for 30 min, and the absorbance was read on an
enzyme-linked immunosorbent assay (ELISA) plate reader (Labsystems Multi-
scan MS, Finland) at 450 nm (1).
Immunoblot analysis. Four micrograms of gp63 were subjected to 10% SDS-
PAGE and electrophoretically transferred to nitrocellulose for immunoblotting.
Immunoblot assays were performed as described previously (54) with slight
modifications. The nitrocellulose strips were first saturated and then blocked
overnight at room temperature in 100 mM Tris-buffered saline (pH 7.6) con-
taining 0.1% Tween 20 and washed once for 15 min with 0.05% Tween 20 in 100
mM Tris-buffered saline (pH 7.6) (washing buffer) with shaking. Incubation of
the nitrocellulose strips with a 1:500 dilution of serum samples from mice im-
munized with gp63 in liposomes, free gp63, or PBS was carried out at room
temperature followed by three washes performed for 20 min per wash. The blots
were then washed and incubated with peroxidase-conjugated anti-mouse IgG
(Sigma-Aldrich) at a 1:500 dilution in the washing buffer for 1 h at room
temperature; this was followed by three washes performed as described above.
The last wash was done without Tween 20. Enzymatic activity was revealed by use
of 15 mg of 3,3-diaminobenzidine tetrahydrochloride in 30 ml of Tris-buffered
saline (pH 7.6) containing 15 l of 30% H2O2.
For immunoblotting of macrophage membrane fractions, macrophages from
the vaccinated mice were isolated in ice-cold PBS and suspended at a concen-
tration of 2  106 cells in 1 ml of 5 mM cold Tris-HCl buffer (pH 7.6). The
macrophage membrane fractions were prepared as described previously (34) for
LAg isolation from L. donovani promastigotes. Immunoblotting was carried out
as described above using rabbit anti-gp63 IgG (1:500 dilution) as the first anti-
body and peroxidase-conjugated anti-rabbit IgG (1:1,500 dilution) as the second
antibody (Sigma-Aldrich).
Evaluation of infection. At 3 months postchallenge, the course of infection was
evaluated by microscopic examination of Giemsa-stained impression smears of
liver and spleen samples. The parasite load was expressed in Leishman-Donovan
units and was calculated by the following formula: number of amastigotes per
1,000 cell nuclei  organ weight (in milligrams) (34).
Macrophage infections. Macrophages collected by peritoneal lavage from im-
munized BALB/c mice 10 days after the last booster injection were allowed to
adhere to glass coverslips (18 mm2; 106 macrophages/coverslip) in 0.5 ml RPMI
1640 containing 10% FBS at 37°C in a humidified chamber containing 5% CO2.
After 2 h, the nonadherent cells were removed by washing with warm PBS and
adhered macrophages were infected with promastigotes at a ratio of approxi-
mately 10 cells per macrophage for another 3 h. The unphagocytosed parasites
were removed by PBS washing, and the infected macrophages were further
incubated in complete medium at 37°C for 72 h. The cells were then fixed in
methanol and stained with Giemsa for determination of intracellular parasite
numbers. Prior to fixation, culture supernatant fluids were removed at 72 h and
frozen at 70°C for future analysis (34).
gp63-specific cytokine production. Spleens were removed aseptically from
individual mice of each group at 10 days or 12 weeks after vaccination and at 3
months postinfection. Each spleen was filtered through a 20-m-pore-size sieve
for preparation of a single-cell suspension in complete medium prepared with
RPMI 1640 containing 10 mM NaHCO3, 10 mM HEPES, penicillin (100 U/ml),
streptomycin (100 g/ml), 50 M -mercaptoethanol, and 10% FBS. Erythro-
cytes were removed by lysis with 0.14 M Tris-buffered NH4Cl. The splenocytes
were washed twice and resuspended in the culture medium, and viable mono-
nuclear cell numbers were determined by trypan blue exclusion (1). Aliquots of
viable cells were incubated with anti-CD4 and anti-CD8 monoclonal antibodies
or the respective control IgGs at a concentration of 1 g/million cells for 1 h at
4°C and washed twice in complete medium. The efficiency of depletion was
checked for each experiment by flow cytometry. Total and CD4- or CD8-de-
pleted splenocytes (14) were stimulated in vitro with medium alone or with
purified native gp63 (1.25 g/ml) for 72 h. The supernatants collected were
stored at 70°C for cytokine analysis.
Measurement of IFN-, IL-4, and IL-12 levels was carried out as detailed in
the instructions supplied with a cytokine ELISA kit (BD Biosciences). The lower
limits of detection for IFN-, IL-4, and IL-12 were 15 pg/ml, 7.8 pg/ml, and 7.8
pg/ml, respectively.
Measurement of NO production. Nitric oxide (NO) levels, quantified by the
accumulation of nitrite in the culture medium, were measured as described
previously (34). Briefly, 100 l of culture supernatants was mixed with an equal
volume of Griess reagent (1% sulfanilamide and 0.1% N-1-naphthylethylene
diamine hydrochloride in 50% H3PO4) and incubated at room temperature for
10 min. Absorbance at 540 nm was then measured. The amount of nitrite
released was quantified by comparison with the NaNO2 level as the standard.
Flow cytometry. All the monoclonal antibodies used were purchased from BD
Biosciences. Appropriately labeled isotype controls and single- or double-color-
stained cells were always used to define the specific gates. Single-cell splenocyte
suspensions were stimulated overnight with 5 g/ml gp63 or left unstimulated.
Following incubation with brefeldin A (10 g/ml) for 4 h, cells were washed with
PBS–1% FCS–0.01% sodium azide, blocked with 10% normal mouse serum, and
incubated with FITC-conjugated anti-CD4 or CD8 MAbs at 4°C for 45 min. For
intracellular staining, cells were permeabilized with Perm-2 followed by washing
with the above-described buffer containing 0.1% saponin and were then reacted
with phycoerythrin-conjugated anti-IFN- or anti-IL-4 MAbs. After proper
washing, cells were fixed in 4% paraformaldehyde and analyzed on a FACSCali-
bur flow cytometer (Becton Dickinson, San Jose, CA) using CellQuest software.
Typically, 0.5 million cells were analyzed per sample. Specific confidence intervals at
a P value of 0.05 are noted in the text.
Microscopy. An aliquot (40 to 50 l) of L. donovani promastigotes or amastigotes
(2 to 4 106/ml) in PBS was immobilized on poly-L-lysine-coated coverglasses at 4°C
for 30 min. Peritoneal macrophages from liposomal gp63-immunized or normal
mice were collected and allowed to adhere on glass coverslips for 2 h at 37°C as
described above for macrophage infections.
For confocal microscopy, the cells were fixed with 1% formaldehyde in PBS for
15 min at room temperature. Following PBS washing and blocking with 3%
bovine serum albumin for 30 min, cells were reacted with FITC-anti-gp63 IgG or
FITC-normal IgG (20 g/ml) for 30 min at room temperature. After the last
washing, cells were mounted using 10% glycerol–PBS and immediately viewed
and photographed using a TCS-SP Leica (Heidelberg, Germany) confocal mi-
croscope system.
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Statistical analysis. Data comparisons were tested for significance by using an
unpaired, two-tailed Student’s t test and two-way or one-way analysis of variance
(ANOVA) as required. P values of 	0.05 were considered significant.
RESULTS
L. donovani gp63 isolation and characterization. We puri-
fied gp63 from L. donovani promastigotes through three steps
(detergent solubilization, ConA-Sepharose affinity chromatog-
raphy, and DEAE-cellulose ion-exchange chromatography)
(Fig. 1A) and confirmed the purity of the protein by two-
dimensional PAGE (Fig. 1B). Recombinant technology offers
easy large-scale isolation of proteins, but it involves the loss of
the native structure of the molecules. Expression of functional
gp63 requires extensive posttranslational modifications, which
are absent when gp63 expression is generated externally (35).
The native structure of gp63 has been reported to be important
for vaccination, as recombinant gp63 either failed to induce
protection or induced only partial protection compared to the
better protection observed with native protein (19, 22, 56).
Hence, in our vaccination experiment we used native gp63,
which was obtained in mass by incubating SLAg with anti-gp63
rabbit IgG coupled to CNBr-activated Sepharose. The se-
quence of gp63 from L. donovani strain AG83 differs in two
amino acids from predicted gp63 sequences of L. donovani, L.
chagasi, and L. infantum (the species causing VL), three from
that of L. amazonensis, four from that of L. major native gp63,
and more from those of other cutaneous and mucocutaneous
Leishmania species with respect to their 16 NH2-terminal
amino acid sequences (Fig. 1B) (76). These differences may be
of significance for the immunogenicity of the protein, as a
single amino acid substitution in this region can cause drastic
change in the molecule or alter the nature of the immune
response (35, 57). We also demonstrated the presence of gp63
on both promastigote and amastigote forms of the parasite
(Fig. 1C) by immunofluorescence, further identifying it as a
good candidate molecule for the study of vaccine efficacy.
L. donovani gp63 encapsulated in liposomes protects
BALB/c mice in a dose-dependent manner. The dose level of a
foreign antigen determines the outcome of an immune re-
sponse irrespective of its nature and route of immunization
and might be a crucial factor in optimizing long-term T-cell
immunity (3, 49, 60). To address the possible contribution of
the level of a gp63 dose, we immunized mice with graded doses
of gp63 (free or entrapped in liposomes) and infected them 10
days after the last immunization. Protection induced by lipo-
somal gp63 in the liver was higher (P 	 0.05, as determined by
two-way ANOVA) at all doses compared to that obtained with
free gp63 (Fig. 2A). Mice receiving 2.5 g gp63 in liposomes
acquired the highest resistance to hepatic infection with L
donovani (86%; P 	 0.05) compared to control results. Immu-
nizing mice with liposomal gp63 at lower (0.6 and 1.25 g) and
higher (5 and 10 g) doses led to significantly higher (as de-
termined by one-way ANOVA) parasitic burden than a dose of
2.5 g. Similarly, free gp63 conferred maximum (55%) protec-
tion at the intermediate dose of 2.5 g, and higher and lower
doses resulted in increased parasitemia. In the spleen, the
protection, although higher when liposomal gp63 was used,
demonstrated statistical significance at doses of 1.25 and 2.5 g
compared to free gp63 results. A dose of 2.5 g of gp63 in
liposomes induced the highest (81%) resistance to L. donovani
compared to the results seen with lower and higher doses of
antigen (P 	 0.05). Dose-dependent protection in BALB/c
mice correlated with cell-mediated immunity, as assessed by
FIG. 1. Purification and characterization of L. donovani gp63.
SLAg (SLA) from L. donovani promastigotes was subjected to affinity
chromatography on ConA-Sepharose resin equilibrated with 5 mM
Tris HCl (pH 7.6)–0.1% octyl--D-glucopyranoside, and the bound
proteins were eluted in the same buffer with 0 to 500 mM linear
methyl--D-mannopyranoside gradient. A pool of enriched ConA-
Sepharose fractions was further loaded onto a DEAE-cellulose col-
umn equilibrated with 5 mM Tris-HCl (pH 8.5)–0.2% Zwittergent
3.12. The elution of gp63 was performed with a linear gradient of 0 to
500 mM NaCl. (A) Silver-stained 10% SDS-PAGE gels showing (from
left to the right) SLAg (6 g), proteins eluted from ConA Sepharose
resin (6 g), and purified gp63 (4 g) through use of a DEAE-cellulose
column. The numbers at the left represent apparent molecular masses
in kilodaltons. (B) Two-dimensional PAGE of purified gp63 (4 g)
stained with ammoniacal silver nitrate solution. The arrow at the right
side of the panel indicates the amino acid sequence of native gp63 at
the NH2 terminus. (C) L. donovani promastigotes and amastigotes
were fixed in formaldehyde followed by staining with 20 g/ml rabbit
anti-gp63 FITC-IgG and studied by both phase-contrast and confocal
microscopy. Cells treated with identical concentrations of normal rab-
bit-FITC IgG served as controls. The photographs are representative
of the results of one of three similar studies.
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FIG. 2. Dose-dependent immune response to infection with L. donovani elicited by the use of gp63 in positively charged liposomes (lip). Mice were
immunized i.p. with graded doses of gp63, free or in association with liposomes, and 10 days after the last immunization they were challenged
intravenously with 2  107 freshly transformed promastigotes. (A) Parasite burdens in the liver and spleen at 3 months postinfection. (B) LAg-specific
DTH responses in immunized and challenged mice expressed as the differences (in millimeters) between the thicknesses of the test (LAg-injected) and
control (PBS-injected) footpads. (C) Reactivity of gp63 with vaccinated mouse serum samples. Blots of gp63 (4 g) were probed with 1:500 dilutions of
serum samples from mice immunized with liposome-encapsulated gp63 (lane 1), free gp63 (lane 2), and PBS (lane 3). (D) Serum IgG1 and IgG2a
antibody responses in vaccinated mice before and after L. donovani challenge were determined by ELISA using gp63-coated microtiter plates incubated
overnight with a 1:100 dilution of sera as described in Materials and Methods. Data represent means 
 standard errors of the means of the results
obtained with four individual mice. *, ANOVA and Tukey’s tests showed significant decreases in parasite load for mice immunized with different doses of
liposome-encapsulated gp63 versus free gp63 (P	 0.05). The results obtained in comparisons of the maximum decreases in parasite load in mice immunized
with 2.5 g gp63 in liposomes to the results obtained with other doses were statistically significant (P 	 0.05) (#, ANOVA and Tukey’s tests).
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DTH response (Fig. 2B). We found a gradual increase in DTH
response with increasing doses of free gp63 after 10 days of
vaccination, but the responses became comparable at all doses
after 3 months of infection. Immunization with 2.5 g liposo-
mal gp63 induced the highest level of DTH before, as well as
after, challenge infection, correlating with the highest resis-
tance observed in this group. DTH levels dropped in mice with
doses lower and higher than 2.5 g gp63 in liposomes. As DTH
response correlates with cell-mediated immunity, its fall thus
explains the reduced protection observed for groups of mice.
Dose-dependent modulation of the humoral response was also
observed in our vaccine study. Free gp63 induced a smaller
amount of antibodies after immunization and an increased
amount after infection (Fig. 2C). Following immunization with
lower (0.6 and 1.25 g) doses of liposomal gp63, higher IgG1
and IgG2a levels were observed, more significantly in postchal-
lenge serum samples. The intermediate dose (2.5 g) that
corresponded to effective protection induced substantially
higher levels of gp63-specific IgG2a than of IgG1. Further
increases in antigen dose levels led to increases in IgG1 pro-
duction. Consistent with previous observations (3), our results
suggest that a low, 2.5-g dose of liposomal gp63 induces
DTH, probably mediated by Th1 (as evidenced by IgG2a pro-
duction), corresponding with protection. Higher doses initiate,
in addition, induction of IgG1 antibodies, demonstrating a
mixed Th1/Th2 response and a decline in resistance. Doses
lower than 2.5 g are insufficient to promote cell-mediated
responses and produce only low levels of IgG1 antibodies,
probably by weak TCR ligation, which might result in differ-
entiation of CD4 T cells with respect to Th2 (7). Our results
therefore demonstrate that optimization of the antigen dose is
crucial for designing a vaccine against such slowly replicating
organisms.
Vaccination with liposomal gp63 confers durable protection
in BALB/c mice following challenge with L. donovani. In con-
trast to the natural resistance to hepatic infection reported for
other strains of L. donovani in infections of BALB/c mice (10),
infection with L. donovani AG83 results in a progressive mul-
tiplication of parasites in the liver and spleen, causing pro-
nounced hepatosplenomegaly (34). In this report we have
shown that i.p. administration of leishmanial antigens (LAg) in
liposomes was sufficient to confer protection in this susceptible
BALB/c model (34). Immunization with the optimal dose of
liposomal gp63 (2.5 g), an immunodominant component of
LAg (1), further demonstrated that induction of protection in
the liver and spleen was possible through use of this defined
antigen when mice were challenged 10 days postvaccination
(Fig. 3A). Protection induced by this vaccine also demon-
strated a significant reduction (P 	 0.05) in the organ weight
compared to the results seen with animals receiving only PBS
or empty liposomes. In contrast, immunization with gp63 alone
could arrest only hepatomegaly (Fig. 3A). Spleen cells of gp63-
liposome-immunized animals were indeed immunogenic, as
adoptive transfer of these cells to naı¨ve mice resulted in de-
monstrable reduction in parasite burden and organ weight at 3
months postinfection (Fig. 3B).
We next determined the durability of the immune response
induced by vaccination with liposomal gp63. To this end, mice
immunized for short-term protection were infected 12 weeks
postvaccination and killed 3 months postinfection. Immunity
elicited by liposomal gp63, but not gp63 or liposome alone, was
durable, with enhanced resistance even when mice were chal-
lenged 12 weeks after vaccination (Fig. 3C). Moreover, mice
(10 per group) immunized with gp63 in liposomes showed
100% survival in response to L. donovani infection until 3
months postinfection, when 30 to 50% of gp63-, liposome-, and
PBS-immunized mice died of heavy infection. These data,
therefore, demonstrate that gp63, as a single antigen in lipo-
somes, can induce effective protection not only against short-
term but also against long-term infection that is sustained in
the susceptible organs of BALB/c mice until at least 3 months
of infection.
Liposomal gp63 vaccination stimulates macrophages to pro-
duce IFN-, IL-12, and nitric oxide and enhances IFN- pro-
duction from mice splenocytes in vitro. To ascertain the vac-
cine-induced activation of macrophages to limit parasite
multiplication, resident peritoneal macrophages were isolated
from immunized BALB/c mice and incubated with L. donovani
promastigotes for 3 h. The numbers of infected macrophages
from mice immunized with free gp63 and liposomal gp63 were
significantly lower (Fig. 4A) (P	 0.05) compared to the results
seen with PBS and empty liposomes, suggesting that immuni-
zation with gp63 affects the initial entry of the parasite into
macrophages. gp63 remained localized on the surface of mac-
rophages from gp63-liposome-immunized mice in a patched
pattern, as revealed by FITC-labeled anti-gp63 antibody re-
sults and as additionally confirmed when macrophage ghost-
membrane immunoblots were probed with anti-gp63 (Fig. 4B).
In contrast, no binding of gp63 was detectable on macrophages
from PBS-immunized mice. These data suggest that blocking
of parasite uptake in macrophages from gp63-immunized mice
might be due to loading of gp63 onto its surface receptors (4).
In these macrophages, infection was arrested compared to
control macrophage results, which showed parasites multiply-
ing progressively (Fig. 4C). Since stimulated macrophages pro-
duce IL-12 and IFN- in response to intracellular pathogens
(68), we investigated the production of these cytokines in 72-h
supernatants of the macrophages from immunized mice in-
fected in vitro. While IFN- was released by macrophages
from both free gp63- and liposomal gp63-immunized mice,
IL-12 was induced only by macrophages through gp63-lipo-
some immunization (Fig. 4D). The simultaneous production of
IFN- and IL-12 in these macrophages correlated with en-
hanced production of NO (Fig. 4D) and almost complete elim-
ination of the parasites. Together, these results imply in vivo
stimulation of the macrophages by liposomal gp63 to produce
Th1-promoting cytokines to facilitate Leishmania clearance by
inducing NO production.
Although IL-12-dependent production of IFN- is the chief
mechanism of protection in vaccine-induced sustained immu-
nity against L. major infection (59), a parasite-specific Th1
immune response is insufficient to confer protective immunity
to L. donovani (37). Therefore, to assess the immune corre-
lates of protection in this model, we evaluated antigen-specific
IFN-, IL-12, and IL-4 from splenocytes of mice after in vitro
stimulation. IFN- was detected postvaccination and postchal-
lenge infection only in groups of mice able to control infection,
that is, those given free gp63 and gp63 in liposomes and chal-
lenged 10 days later and those given gp63 in liposomes and
challenged 12 weeks later (Fig. 4E and F). IL-12, however, was
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produced only by cells from mice immunized with liposomal
gp63 and vaccinated before infectious challenge and after in-
fectious challenge at 10 days but not at 12 weeks (Fig. 4G),
indicating that persistent IL-12 might not be required in this
model. To investigate the cellular source of IFN-, anti-CD4
and anti-CD8 monoclonal antibodies were added to the
cultures. Addition of anti-CD4 substantially inhibited the
production of IFN- from cells of all the groups able to
control infection (Fig. 4E and F). Addition of anti-CD8
reduced IFN- levels only for the cells of mice vaccinated
with liposomal gp63, indicating a role for CD8 T cells in
immunity induced in this group. CD4 T cells from mice
vaccinated with free gp63 and with gp63 in liposomes also
secreted IL-4, levels of which decreased substantially 3
FIG. 3. Evaluation of protection against visceral leishmaniasis in BALB/c mice. Animals were immunized i.p. and were twice given booster
injections at 2-week intervals with PBS, with empty liposomes (Lip), and with free gp63 or gp63 entrapped in cationic liposomes (lip). (A) Parasite
burden and organ weights in the liver and spleen of mice challenged 10 days after the last immunization were determined at 3 months. Data are
representative of the results of two independent experiments. (B) Splenocytes (2  107) of mice after 10 days of vaccination were transferred to
naı¨ve mice, and 7 days postvaccination the animals were challenged. The parasite load and organ weights were examined in the liver and spleen
after 3 months. Photographs of the spleens of infected controls and vaccinated animals are shown at upper right. (C) In a separate experiment,
mice were immunized with PBS, empty liposomes, or gp63 alone or in association with liposome and were challenged 12 weeks after vaccination.
At the end of 3 months of infection, liver and spleen parasite loads and corresponding organ weights were determined. Data represent
Leishman-Donovan units (LDU)
 standard errors of the means and organ weights
 standard errors of the means determined for individual mice
(n  3 or 4). Significant (*, P 	 0.05; **, P 	 0.01; ***, P 	 0.001) differences in the results were obtained using vaccinated versus control mice,
as determined by Student’s t test.
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FIG. 4. Macrophages and T cells are involved in the control of L. donovani infection. BALB/c mice were immunized with free or liposome-
encapsulated (lip) gp63 as described in Materials and Methods. Control mice received PBS and empty liposomes (Lip). (A) Peritoneal macro-
phages were collected from different groups of mice followed by in vitro infection with L. donovani, and percentages of infected macrophages were
determined. *, Student’s t test revealed statistically significant (**, P 	 0.01; ***, P 	 0.001) decreases of infection in animals immunized with
free- and liposome-encapsulated gp63 versus PBS control results. (B) Presence or absence of gp63 on macrophage surfaces of PBS-vaccinated mice
(left panel) and liposomal gp63-vaccinated mice (right panel) as observed by confocal microscopy. A Western blot employing polyclonal anti-gp63
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months after infection compared to the results seen with
infected control mice (Fig. 4E and F).
Immunization with gp63 in liposomes induces CD4 and
CD8 T-cell production of IFN- in mice sustaining long-term
immunity. Direct evidence for CD4 and CD8 T-cell pro-
duction of IFN- was obtained by measuring the frequencies of
these cells in the spleen. There were demonstrable numbers of
CD4 cells producing IFN- in mice vaccinated with both free
and liposomal gp63 10 days after vaccination (Fig. 5A). How-
ever, CD4 T cells producing IFN- were detected 12 weeks
after vaccination only in cells of mice vaccinated with gp63 in
liposomes. After 3 months of infection, the frequencies of
CD4 IFN--producing cells from mice initially vaccinated
with gp63 and gp63 in liposomes and infected 10 days later
were enhanced further (Fig. 5B), correlating with protection
in these groups. Cells of mice vaccinated with liposomal
gp63 and infected 12 weeks later also demonstrated an in-
crease in frequencies of CD4 IFN--producing T cells after
infection. In addition, enhanced frequencies of CD8-pro-
ducing IFN- cells were detected only in animals infected 12
weeks postvaccination, correlating with long-term protective
immunity in this group. Immunization with gp63 alone is
insufficient to maintain CD4 and CD8 T-effector cells
producing IFN-, resulting in failure to control infection 12
weeks after vaccination.
As for IL-4 production, mice vaccinated with liposomal gp63
had low numbers of CD4 cells producing IL-4 (Fig. 5C). The
frequencies of IL-4-producing cells were similar for mice able
to control infection 10 days after vaccination with free gp63
and vaccination with gp63 in liposomes, but these levels were
lower than those seen with mice vaccinated with PBS (Fig. 5D).
However, mice infected with free gp63 at 12 weeks after vac-
cination had higher frequencies of IL-4-producing CD4 cells.
In contrast, mice vaccinated with liposomal gp63 had ex-
tremely low frequencies of cells producing IL-4 in comparison
to mice in the control group.
DISCUSSION
Herein we report, for the first time, the induction of
long-term protective immunity by a defined protein antigen
vaccine entrapped in cationic DSPC liposomes. Immuniza-
tion of susceptible BALB/c mice with gp63 entrapped in
these vesicles protected virtually all of the mice against
progressive nonhealing infections with L. donovani. More-
over, the potent and durable protection was elicited by a
low-dose protein antigen formulated in liposome carriers
without the use of immunomodulating adjuvants such as
IL-12 DNA or CpG oligonucleotides. These data strongly
suggest that effective protein vaccines can be successfully
used for inducing durable immunity against diseases requir-
ing cellular immune responses when delivered in association
with cationic DSPC liposomes.
Our data demonstrating that gp63 encapsulated in stable
cationic liposomes provides long-term protection are in con-
trast to previous studies of protein-based vaccines (14, 38). In
a study by Gurunathan et al. (14), vaccination of BALB/c mice
with both SLAg and recombinant LACK plus recombinant
IL-12 failed to control infection when mice were challenged
with L. major 12 weeks after immunization. Similarly, long-
term protection against CL could not be demonstrated in a
natural self-curing model (using C57BL/6 mice) when mice
were vaccinated with leishmanial antigen and recombinant
IL-12 (38). The elicitation of potent durable protection re-
quired vaccination with either plasmid DNAs encoding Leish-
mania antigen or antigens plus IL-12 DNA (14, 38). Although
DNA vaccines have proved effective in the murine system, they
are far less immunogenic in humans (15). CpG oligonucleo-
tides can generate strong cellular responses against protein
antigens. CpG oligonucleotides are effective as vaccine adju-
vants when high doses of antigen are administered (39, 53).
Moreover, there are several safety concerns regarding the clin-
ical use of CpG oligonucleotides (31). Cationic DSPC lipo-
somes, representing the vaccine adjuvant used in our study, are
relatively inert in terms of activating immune responses, are
nontoxic, and require low doses of antigen (5, 9). The experi-
ments producing the results presented here showing that these
liposomes provide long-term protection have been repeated
with consistent results and little variability. Moreover, this vac-
cine adjuvant elicited sustained and durable protection when
used with either LAg (unpublished observation) or purified
protein.
Induction of significant short-term as well as long-term re-
sistance in both livers and spleens of susceptible mice, in a
model using purified antigen which closely mimics clinical pa-
thology associated with human VL, has not been observed in
other laboratory-based trials of VL vaccine. Only a few defined
antigens (dp72, Lcr1, recombinant hydrophilic acid surface
protein B1 [rHASPB1], A2, recombinant open-reading frame
[rORFF]) have been evaluated as vaccine candidates for pro-
tection against VL (12, 23, 62, 65, 66). Of these, rHASPB1 and
rORFF have been described as inducing long-term protection
(62, 66). However, in these studies mice were challenged
after only 3 weeks had passed after the last vaccination.
Moreover, rORFF antigen conferred protection when coad-
ministered with IL-12 DNA, an approach not desirable for
antibody for gp63 liposome-immunized macrophage membrane fractions was used to produce the photographs. (C) Immunization induced
activation of macrophages to suppress intracellular amastigote proliferation 72 h after infection in vitro with L. donovani. (D) IFN-, IL-12, and
NO production by macrophages after 72 h of infection. ND, not detected. (E) Single-cell suspensions were prepared from harvested spleens of
vaccinated animals before and after challenge infection, and portions were treated with media alone and anti-CD4 and anti-CD8 monoclonal
antibodies as described in Materials and Methods. Total cells and T cells depleted of CD4 and CD8 were plated in 24-well tissue culture plates
and stimulated in vitro with gp63 (1.25 g/ml). At 72 h later, supernatants were harvested and IFN- and IL-4 levels were determined by ELISA.
(F) Spleen cells of mice vaccinated at 12 weeks were harvested before and after infection with L. donovani and treated with anti-CD4 or anti-CD8
monoclonal antibodies as described above, and levels of in vitro production of IFN- and IL-4 from 72-h culture supernatants were estimated. (G)
Production of IL-12 by splenocytes before infection (open bar) or after infection (closed bars). The data represent means 
 standard errors of the
means of the results obtained with three individual mice. ND, not detected.
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human administration. Protection induced by rHASPB1 did
not require an adjuvant. However, the level of protection
did not exceed 50% at the peak liver burden. Immunization
with gp63 purified from L. donovani promastigotes also re-
sulted in partial protection in the absence of adjuvant in
BALB/c mice. The protective efficacy was markedly en-
hanced in association with liposomes inducing short-term as
well as long-term resistance to challenge with virulent L.
donovani parasites.
In terms of immune correlates of protection, the roles of
FIG. 5. Th1 responses that are dominant over Th2 responses control L. donovani infection. The frequencies of CD4 and CD8 T cells
producing IFN- and IL-4 in the indicated groups were assessed using single-cell splenocyte suspensions left unstimulated or restimulated
overnight with gp63 (5 g/ml). (A) The frequencies of cells producing IFN- were assessed 10 days after vaccination both before and after 3 months
of infection. lip, liposome encapsulation; Lip, empty liposomes. (B) The frequencies of cells producing IFN- were assessed 12 weeks after
vaccination both before and after 3 months of infection. (C) Mice were challenged with L. donovani at 10 days, and the frequencies of cells
producing IL-4 were determined at 3 months both before and after infectious challenge. (D) Frequencies of cells producing intracellular IL-4 were
also determined in animals at 12 weeks postimmunization both before and after 3 months of infectious challenge. Data represent means
 standard
errors of the means of the results obtained with three individual mice.
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CD4 and CD8 T cells have been well documented for long-
term, vaccine-induced resistance to Leishmania spp. (16, 27,
77). Induction of potent Th1 responses by cationic liposomes
(5, 24) is consistent with our findings that mice vaccinated with
gp63 in liposomes exhibited striking enhancements of the fre-
quency and production of IFN- from CD4 T cells both
before infectious challenge and at 10 days or 12 weeks after
infectious challenge. Significant frequencies of antigen-specific
CD8 IFN- cells were demonstrable only in the protected
mice challenged 12 weeks after vaccination, supporting the
idea of the importance of CD8 T cells in mediating long-term
immunity (16, 53). Our data demonstrating an ability to elicit
CD8 T-cell responses by use of cationic DSPC liposomes with
a defined protein antigen are comparable to those obtained
with CpG ODN and DNA vaccination. Control of VL requires
IFN- (72), which was sufficiently produced and maintained
for at least 12 weeks after vaccination with cationic liposome-
encapsulated gp63, and the amount was enhanced at 3 months
following L donovani infection. IL-12, which is produced by
APCs such as macrophages and dendritic cells at the initiation
of immune response, is the inducer cytokine for IFN- and
activates macrophages and potentiates their microbicidal ac-
tivities (60). However, in many experimental models of intra-
cellular infections, including L. major infections, maintenance
of CD4 IFN- production has been reported to depend on
the continuing presence of IL-12, although CD8 T-cell pro-
duction of IFN- may be IL-12 independent (14, 64). In con-
trast, studies of murine models of L. donovani infection dem-
onstrating induction of comparable levels of IFN- by
rHASPB1 immunization with and without IL-12 and resistance
to infection in IL-12 p35 knockout mice have suggested that
IL-12 is not required to maintain immunity against this para-
site (41). Our data showing IL-12 production after short-term
immunization indicate a role for IL-12 in at least the initiation
of a Th1 response. The lack of IL-12 following long-term
immunization suggests that once the protective responses are
established, immunity in this model is sustained without IL-12.
Disease progression in the present model corresponded to the
presence of IL-4 and a lack of IFN- production by splenic T
cells. IL-4 was also produced in spleen cells of vaccinated mice
after immunization. However, the level of IL-4 decreased sig-
nificantly at 3 months postinfection compared to infected con-
trol results. Notably, our results, though not providing direct
evidence, are in line with observations revealing that IL-4 is
crucial for the priming of long-term CD8 T-cell memory
responses (20, 40, 63). As IL-4 and IFN- influence antibody
class switching, assessment of antigen-specific production of
antibody subtypes provides an indirect but physiologic corre-
late of the pattern of cytokine production in vivo. Protected
mice had an increase in IgG2a levels (consistent with increased
IFN- levels). They also produced IgG1, although the level was
significantly lower than that seen with unprotected mice, sug-
gesting the presence of IL-4 as well. Vaccination with gp63 in
association with cationic DSPC liposomes thus elicited both
cell-mediated and humoral immune responses. After immuni-
zation, subsets of CD4 cells and of Th1 and Th2 cells were
activated. Protection in vaccinated mice corresponded to a
dominant Th1 response, a downregulation of Th2 response,
and a CD8 T-cell response associated with long-term immu-
nity.
The efficacy of our vaccine may be due to several factors.
First, we used native gp63 versus recombinant gp63. Moreover,
this antigen is immunodominant and associated with virulence
of L. donovani (1, 71). Second, we determined that there is an
antigen dose level that provides optimum protection, which
confirms and extends previous observations that immunogen
doses influence the generation of Th1/Th2 cells (3, 49, 60).
Third, cationic liposomes demonstrate efficient interaction
with APCs for a combination of CD4 and CD8 T-cell re-
sponses (5, 11, 44, 45, 50). These vesicles have been observed
to increase the immunogenicity of the antigens and prevent
their degradation in vivo (5). Formulation of the antigen-con-
taining cationic liposomes with DSPC, as shown in our studies,
may serve to protect the antigen further and thereby improve
antigen-delivering capacity (8, 13, 70). The presence of choles-
terol in the vesicles facilitates cytoplasmic release of the anti-
gens, avoiding lysosomal degradation (17). Increased in vivo
stability of these vesicles may further promote stimulation of
CD8 T-cell responses (21). Membrane antigens in DSPC
liposomes have been reported to be transferred to plasma
membrane of APCs without being processed (13, 70). Since we
also obtained signals for the presence of intact gp63 on the
surface of macrophages from immunized mice, we propose in
addition that it is the direct transfer of gp63 onto macrophage
surfaces, facilitated by the presence of its receptors (4), that
may be responsible for prevention of the parasites from estab-
lishing infection.
Most licensed vaccines, particularly those incorporating at-
tenuated live products or killed whole-cell products, contain all
the components necessary for an integrated immune response.
Thus, leishmanization remains the gold standard for vaccina-
tion and life-long protection against this disease. Leishmania
parasites are probably never completely eliminated by therapy,
and several studies of murine models have indicated the im-
portance of persistent parasites in establishing an effective
protective memory response (2, 69). Due to unacceptable ad-
verse effects associated with whole parasites, attention has now
turned toward safer and better-defined subunit vaccines (6).
However, isolated antigens from such chronic infections often
lack sufficient immunogenicity, thus requiring the addition of
potent adjuvants which, in addition to enhancing antibody pro-
duction, are specifically geared to generation of cell-mediated
immunity (47, 48). Cationic liposomes are safe adjuvants, as
demonstrated by the fact that they are exploited worldwide in
human gene therapy (61). The observations demonstrating
that stable cationic liposomes, when used as an adjuvant with
purified protein antigen, can induce long-term protection
against an intracellular infection have shown that these vesicles
are potent vaccine adjuvants for diseases requiring cellular
immunity.
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